文献速递免疫规划传染病防控与疫情报告

2010-2015年中国疫苗受种者疫苗相关麻痹型脊髓灰质炎

Recipient vaccine-associated paralytic poliomyelitis in China, 2010-2015.
PubMed 文献 · Vaccine · 2018-01-01

基于中国免疫规划不良事件信息系统2010-2015年被动监测数据,报告157例受种者疫苗相关麻痹型脊髓灰质炎(VAPP),男女性别比8.2:1,151例(96.2%)不足6个月龄,全部与三价口服脊髓灰质炎疫苗(tOPV)相关,89.8%发生于首剂接种后。以OPV接种剂次为分母估算发病率为0.4/百万剂,以估计出生数为分母估算每百万出生中VAPP为1.0至2.4例。作者建议使用灭活脊髓灰质炎疫苗以减少中国受种者VAPP病例。

要点

  • 2010-2015年中国报告157例受种者VAPP,男女性别比8.2:1,151例(96.2%)不足6个月龄。
  • 全部病例与tOPV相关,89.8%发生于首剂接种后;以接种剂次为分母估算发病率为0.4/百万剂。
  • 作者建议使用灭活脊髓灰质炎疫苗以减少中国受种者VAPP病例。

核心结论

  • 中国受种者VAPP病例的流行病学特征(如年龄分布)与其他国家既往研究相当。
  • 以估计出生数或接种剂次为分母计算的受种者VAPP风险与美国和日本相当。
  • 作者建议使用灭活脊髓灰质炎疫苗以减少中国受种者VAPP病例。

研究设计与样本

  • 研究从中国免疫规划不良事件信息系统(CNAEFIS,被动监测系统)检索2010-2015年报告的受种者VAPP病例。
  • 研究检查病例的人口学特征,并以行政接种剂次数据和估计出生数作为分母计算VAPP发病率。

主要发现

  • 2010-2015年CNAEFIS共报告157例受种者VAPP,男女性别比8.2:1。
  • 151例(96.2%)不足6个月龄。
  • 全部病例与三价口服脊髓灰质炎疫苗(tOPV)相关,89.8%发生于首剂接种后。
  • 157例中,分别从27例(17.2%)、25例(15.9%)和16例(10.2%)分离出II型、III型和I型脊髓灰质炎病毒疫苗株。
  • 1例死亡、1例完全康复,其余155例存在单侧或双侧跛行等不同程度躯体残疾。

临床怎么用

  • 作者建议使用灭活脊髓灰质炎疫苗以减少中国受种者VAPP病例。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vaccine-associated paralytic poliomyelitis (VAPP) is one of the most important adverse effects of vaccines that are in current use globally. The Chinese national adverse event following immunization information system (CNAEFIS) is a passive surveillance system which collects data on VAPP. AIMS: To describe the epidemiological characteristics of VAPP and estimate the risk of recipient VAPP in China. METHODS: We retrieved information from reported cases of recipient VAPP from CNAEFIS from 2010 to 2015, examined the demographic characteristics of the cases, and used administrative data on vaccination doses and the estimated number of births as denominators to calculate VAPP incidence. RESULTS: During 2010-2015, 157 cases of recipient VAPP were reported to CNAEFIS (male-to-female ratio, 8.2:1); 151 cases (96.2%) were less than six months old. All cases were associated with trivalent OPV (tOPV), and 89.8% occurred after the receipt of first dose. Of the 157 recipient VAPP cases, type II, type III, and type I poliovirus vaccine strains were isolated from 27 (17.2%) , 25 (15.9%) , and 16 (10.2%) cases, respectively. One case died and one case recovered completely; the other 155 cases had various physical disabilities, such as monolateral or bilateral limping. Using the administered doses of OPV as the denominator, the incidence of recipient VAPP during the study period was estimated at 0.4 per million doses. The estimated recipient VAPP per million births ranged from 1.0 to 2.4 during 2010-2015. CONCLUSION: The epidemiological characteristics of recipient VAPP cases in China, such as age distribution, were comparable to those in previous studies from other countries. The risk of recipient VAPP, using either estimated births or vaccination doses, was comparable to that in the US and Japan. We recommend using an inactive poliovirus vaccine to decrease the number of recipient VAPP cases in China.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wu W, Wang H, Li K, et al. Recipient vaccine-associated paralytic poliomyelitis in China, 2010-2015. Vaccine. 2018. PMID: 29395524. doi:10.1016/j.vaccine.2018.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。